InvestorsHub Logo
Followers 5
Posts 1172
Boards Moderated 0
Alias Born 05/13/2017

Re: None

Sunday, 07/22/2018 7:15:45 PM

Sunday, July 22, 2018 7:15:45 PM

Post# of 205098
The FDA really wants this technology Bad, Their whole new paradigm relies on biomarkers Arrayit can supply.

OvaDx® Ovarian Cancer Diagnostic Test,
Diagnostics - Parkinson’s Disease,
Diagnostics - Arrayit Human Rare Disease Analysis using Whole Genome Microarray Expression Profiling and Advanced Bioinformatics to Elucidate Rare Diseases,
Diagnostics - Arrayit Human Orphan Disease Analysis using Whole Genome Microarray Expression Profiling and Advanced Bioinformatics to Elucidate Orphan Diseases, Blood cards, food and Allergy Testing, ect, ect....




Biomarkers at FDA

"The success of personalized medicine fundamentally depends on the development of biomarkers and diagnostic tests that can be used to accurately identify the patient population."

https://www.fda.gov/ScienceResearch/AboutScienceResearchatFDA/ucm519362.htm